PCSK9 and atherosclerosis: While pivotal trials spotlighted the LDL-lowering capabilities of PCSK9 inhibitors, recent studies have focused on the pleiotropic effects of PCSK9 inhibitors on atherosclerosis beyond LDL reduction (24).